[Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype].
Identifieur interne : 002E26 ( Main/Exploration ); précédent : 002E25; suivant : 002E27[Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype].
Auteurs : T A Smolonogina ; Iu A. Desheva ; A R Rekstin ; A N Mironov ; L G RudenkoSource :
- Voprosy virusologii [ 0507-4088 ]
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Anticorps antiviraux (immunologie), Anticorps antiviraux (sang), Grippe humaine (), Grippe humaine (immunologie), Grippe humaine (virologie), Humains, Protection croisée, Rappel de vaccin, Sialidase (génétique), Sialidase (immunologie), Sous-type H2N2 du virus de la grippe A (génétique), Sous-type H2N2 du virus de la grippe A (immunologie), Sous-type H5N2 du virus de la grippe A (génétique), Sous-type H5N2 du virus de la grippe A (immunologie), Sous-type H7N2 du virus de la grippe A (génétique), Sous-type H7N2 du virus de la grippe A (immunologie), Tests de neutralisation, Vaccination, Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Vaccins atténués, Virus recombinants (génétique), Virus recombinants (immunologie), Volontaires sains.
- MESH :
- administration et posologie : Vaccins antigrippaux.
- génétique : Sialidase, Sous-type H2N2 du virus de la grippe A, Sous-type H5N2 du virus de la grippe A, Sous-type H7N2 du virus de la grippe A, Virus recombinants.
- immunologie : Anticorps antiviraux, Grippe humaine, Sialidase, Sous-type H2N2 du virus de la grippe A, Sous-type H5N2 du virus de la grippe A, Sous-type H7N2 du virus de la grippe A, Vaccins antigrippaux, Virus recombinants.
- sang : Anticorps antiviraux.
- virologie : Grippe humaine.
- Adolescent, Adulte, Adulte d'âge moyen, Grippe humaine, Humains, Protection croisée, Rappel de vaccin, Tests de neutralisation, Vaccination, Vaccins atténués, Volontaires sains.
English descriptors
- KwdEn :
- Adolescent, Adult, Antibodies, Viral (blood), Antibodies, Viral (immunology), Cross Protection, Healthy Volunteers, Humans, Immunization, Secondary, Influenza A Virus, H2N2 Subtype (genetics), Influenza A Virus, H2N2 Subtype (immunology), Influenza A Virus, H5N2 Subtype (genetics), Influenza A Virus, H5N2 Subtype (immunology), Influenza A Virus, H7N2 Subtype (genetics), Influenza A Virus, H7N2 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Influenza, Human (virology), Middle Aged, Neuraminidase (genetics), Neuraminidase (immunology), Neutralization Tests, Reassortant Viruses (genetics), Reassortant Viruses (immunology), Vaccination, Vaccines, Attenuated.
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , genetics : Neuraminidase.
- chemical , immunology : Antibodies, Viral, Influenza Vaccines, Neuraminidase.
- genetics : Influenza A Virus, H2N2 Subtype, Influenza A Virus, H5N2 Subtype, Influenza A Virus, H7N2 Subtype, Reassortant Viruses.
- immunology : Influenza A Virus, H2N2 Subtype, Influenza A Virus, H5N2 Subtype, Influenza A Virus, H7N2 Subtype, Influenza, Human, Reassortant Viruses.
- prevention & control : Influenza, Human.
- virology : Influenza, Human.
- Adolescent, Adult, Cross Protection, Healthy Volunteers, Humans, Immunization, Secondary, Middle Aged, Neutralization Tests, Vaccination, Vaccines, Attenuated.
Abstract
In the current study, we evaluated the neuraminidase-inhibition (NI) antibodies among volunteers during the phase I and phase II of the clinical trials of a monovalent live attenuated influenza vaccine (LAIV) A/17/duck/ Potsdam/86/92(H5N2). The reassortant influenza virus RN2/57-human A(H7N2) containing neuraminidase (NA) from the A/Leningrad/134/17/57(H2N2) was used in NI test. It was shown that two doses of the monovalent LAIV A(H5N2) led to a statistically significant increase in the NI antibodies to vaccine strain NA. More than twofold increase in antibodies was obtained among 19.5-33.3% of vaccinated. The microneutralization test and NI assay results coincidence in the same pairs of sera of the vaccinated volunteers was 73.2%, suggesting thus a statistically significant interdependence between the values of increase in antibodies revealed in both tests (p = 0.04).
PubMed: 24772644
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000100
- to stream PubMed, to step Curation: 000100
- to stream PubMed, to step Checkpoint: 000588
- to stream Ncbi, to step Merge: 000A39
- to stream Ncbi, to step Curation: 000A39
- to stream Ncbi, to step Checkpoint: 000A39
- to stream Main, to step Merge: 003001
- to stream Main, to step Curation: 002E26
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype].</title><author><name sortKey="Smolonogina, T A" sort="Smolonogina, T A" uniqKey="Smolonogina T" first="T A" last="Smolonogina">T A Smolonogina</name></author><author><name sortKey="Desheva, Iu A" sort="Desheva, Iu A" uniqKey="Desheva I" first="Iu A" last="Desheva">Iu A. Desheva</name></author><author><name sortKey="Rekstin, A R" sort="Rekstin, A R" uniqKey="Rekstin A" first="A R" last="Rekstin">A R Rekstin</name></author><author><name sortKey="Mironov, A N" sort="Mironov, A N" uniqKey="Mironov A" first="A N" last="Mironov">A N Mironov</name></author><author><name sortKey="Rudenko, L G" sort="Rudenko, L G" uniqKey="Rudenko L" first="L G" last="Rudenko">L G Rudenko</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2013 Nov-Dec</MedlineDate></PubDate></date><idno type="RBID">pubmed:24772644</idno><idno type="pmid">24772644</idno><idno type="wicri:Area/PubMed/Corpus">000100</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000100</idno><idno type="wicri:Area/PubMed/Curation">000100</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000100</idno><idno type="wicri:Area/PubMed/Checkpoint">000588</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000588</idno><idno type="wicri:Area/Ncbi/Merge">000A39</idno><idno type="wicri:Area/Ncbi/Curation">000A39</idno><idno type="wicri:Area/Ncbi/Checkpoint">000A39</idno><idno type="wicri:doubleKey">0507-4088::Smolonogina T:evaluation:of:the</idno><idno type="wicri:Area/Main/Merge">003001</idno><idno type="wicri:Area/Main/Curation">002E26</idno><idno type="wicri:Area/Main/Exploration">002E26</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype].</title><author><name sortKey="Smolonogina, T A" sort="Smolonogina, T A" uniqKey="Smolonogina T" first="T A" last="Smolonogina">T A Smolonogina</name></author><author><name sortKey="Desheva, Iu A" sort="Desheva, Iu A" uniqKey="Desheva I" first="Iu A" last="Desheva">Iu A. Desheva</name></author><author><name sortKey="Rekstin, A R" sort="Rekstin, A R" uniqKey="Rekstin A" first="A R" last="Rekstin">A R Rekstin</name></author><author><name sortKey="Mironov, A N" sort="Mironov, A N" uniqKey="Mironov A" first="A N" last="Mironov">A N Mironov</name></author><author><name sortKey="Rudenko, L G" sort="Rudenko, L G" uniqKey="Rudenko L" first="L G" last="Rudenko">L G Rudenko</name></author></analytic><series><title level="j">Voprosy virusologii</title><idno type="ISSN">0507-4088</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Antibodies, Viral (blood)</term><term>Antibodies, Viral (immunology)</term><term>Cross Protection</term><term>Healthy Volunteers</term><term>Humans</term><term>Immunization, Secondary</term><term>Influenza A Virus, H2N2 Subtype (genetics)</term><term>Influenza A Virus, H2N2 Subtype (immunology)</term><term>Influenza A Virus, H5N2 Subtype (genetics)</term><term>Influenza A Virus, H5N2 Subtype (immunology)</term><term>Influenza A Virus, H7N2 Subtype (genetics)</term><term>Influenza A Virus, H7N2 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Influenza, Human (virology)</term><term>Middle Aged</term><term>Neuraminidase (genetics)</term><term>Neuraminidase (immunology)</term><term>Neutralization Tests</term><term>Reassortant Viruses (genetics)</term><term>Reassortant Viruses (immunology)</term><term>Vaccination</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps antiviraux (immunologie)</term><term>Anticorps antiviraux (sang)</term><term>Grippe humaine ()</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (virologie)</term><term>Humains</term><term>Protection croisée</term><term>Rappel de vaccin</term><term>Sialidase (génétique)</term><term>Sialidase (immunologie)</term><term>Sous-type H2N2 du virus de la grippe A (génétique)</term><term>Sous-type H2N2 du virus de la grippe A (immunologie)</term><term>Sous-type H5N2 du virus de la grippe A (génétique)</term><term>Sous-type H5N2 du virus de la grippe A (immunologie)</term><term>Sous-type H7N2 du virus de la grippe A (génétique)</term><term>Sous-type H7N2 du virus de la grippe A (immunologie)</term><term>Tests de neutralisation</term><term>Vaccination</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Vaccins atténués</term><term>Virus recombinants (génétique)</term><term>Virus recombinants (immunologie)</term><term>Volontaires sains</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Viral</term><term>Influenza Vaccines</term><term>Neuraminidase</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term><term>Influenza A Virus, H5N2 Subtype</term><term>Influenza A Virus, H7N2 Subtype</term><term>Reassortant Viruses</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sialidase</term><term>Sous-type H2N2 du virus de la grippe A</term><term>Sous-type H5N2 du virus de la grippe A</term><term>Sous-type H7N2 du virus de la grippe A</term><term>Virus recombinants</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term><term>Grippe humaine</term><term>Sialidase</term><term>Sous-type H2N2 du virus de la grippe A</term><term>Sous-type H5N2 du virus de la grippe A</term><term>Sous-type H7N2 du virus de la grippe A</term><term>Vaccins antigrippaux</term><term>Virus recombinants</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term><term>Influenza A Virus, H5N2 Subtype</term><term>Influenza A Virus, H7N2 Subtype</term><term>Influenza, Human</term><term>Reassortant Viruses</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Cross Protection</term><term>Healthy Volunteers</term><term>Humans</term><term>Immunization, Secondary</term><term>Middle Aged</term><term>Neutralization Tests</term><term>Vaccination</term><term>Vaccines, Attenuated</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Grippe humaine</term><term>Humains</term><term>Protection croisée</term><term>Rappel de vaccin</term><term>Tests de neutralisation</term><term>Vaccination</term><term>Vaccins atténués</term><term>Volontaires sains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In the current study, we evaluated the neuraminidase-inhibition (NI) antibodies among volunteers during the phase I and phase II of the clinical trials of a monovalent live attenuated influenza vaccine (LAIV) A/17/duck/ Potsdam/86/92(H5N2). The reassortant influenza virus RN2/57-human A(H7N2) containing neuraminidase (NA) from the A/Leningrad/134/17/57(H2N2) was used in NI test. It was shown that two doses of the monovalent LAIV A(H5N2) led to a statistically significant increase in the NI antibodies to vaccine strain NA. More than twofold increase in antibodies was obtained among 19.5-33.3% of vaccinated. The microneutralization test and NI assay results coincidence in the same pairs of sera of the vaccinated volunteers was 73.2%, suggesting thus a statistically significant interdependence between the values of increase in antibodies revealed in both tests (p = 0.04).</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Desheva, Iu A" sort="Desheva, Iu A" uniqKey="Desheva I" first="Iu A" last="Desheva">Iu A. Desheva</name><name sortKey="Mironov, A N" sort="Mironov, A N" uniqKey="Mironov A" first="A N" last="Mironov">A N Mironov</name><name sortKey="Rekstin, A R" sort="Rekstin, A R" uniqKey="Rekstin A" first="A R" last="Rekstin">A R Rekstin</name><name sortKey="Rudenko, L G" sort="Rudenko, L G" uniqKey="Rudenko L" first="L G" last="Rudenko">L G Rudenko</name><name sortKey="Smolonogina, T A" sort="Smolonogina, T A" uniqKey="Smolonogina T" first="T A" last="Smolonogina">T A Smolonogina</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E26 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002E26 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:24772644
|texte= [Evaluation of the anti-neuraminidase antibodies in clinical trials of the live influenza vaccine of the A(H5N2) subtype].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24772644" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |